HBM Healthcare Investments (Cayman) Ltd. 4
4 · Mineralys Therapeutics, Inc. · Filed Feb 16, 2023
Insider Transaction Report
Form 4
HBM BIOVENTURES CAYMAN LTD
10% Owner
Transactions
- Conversion
Common Stock
2023-02-14+1,941,368→ 1,941,368 total - Conversion
Common Stock
2023-02-14+964,238→ 2,905,606 total - Purchase
Common Stock
2023-02-14$16.00/sh+312,500$5,000,000→ 3,218,106 total - Conversion
Series B Preferred Stock
2023-02-14−10,411,846→ 0 total→ Common Stock (964,238 underlying) - Conversion
Series A Preferred Stock
2023-02-14−20,962,895→ 0 total→ Common Stock (1,941,368 underlying)
Footnotes (2)
- [F1]Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series A Preferred Stock had no expiration date.
- [F2]Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person automatically converted, for no additional consideration, into Common Stock. These shares of Series B Preferred Stock had no expiration date.